A physician consultation including health history review and lab work is required to determine if youre a candidate
Novo Nordisk filed a New Drug Application for the CagriSema combination (cagrilintide 2.4 mg + semaglutide 2.4 mg) in December 2025, with an FDA decision anticipated in late 2026
Each vial ships with a Certificate of Analysis documenting: Identity Verification HPLC and Mass Spectrometry Purity Analysis HPLC quantification Endotoxin Screening LAL assay Sterility Microbial contamination screening Heavy Metals Lead, mercury, cadmium analysis Physical Inspection Color, clarity, appearance Traceability Batch numbers, test dates, storage specs Important Notice This product is intended for laboratory research use only
Long-term safety beyond 90 days has not been studied for the combined blend
What viewers often do not see is the discipline around training, diet, sleep and consistency that usually exists alongside these compounds
As subjects were included when either treatment combination was initiated, any previous use of metformin, GLP-1 RA or DPP-4is alone or in combination with any other glucose-lowering drug was allowed